UBS AM’s DexCom DXCM Stock Holding History

UBS AM’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$612M	Buy	9,746,174 +1,747,117	+22%	+$122M	0.13%	143
2025 Q4	$531M	Buy	7,999,057 +516,526	+7%	+$33.4M	0.11%	148
2025 Q3	$503M	Sell	7,482,531 -1,648,083	-18%	-$130M	0.11%	162
2025 Q2	$797M	Sell	9,130,614 -992,911	-10%	-$77.8M	0.16%	121
2025 Q1	$691M	Buy	10,123,525 +2,925,241	+41%	+$239M	0.18%	116
2024 Q4	$560M	Buy	7,198,284 +849,887	+13%	+$62.9M	0.13%	144
2024 Q3	$426M	Buy	6,348,397 +71,893	+1%	+$5.9M	0.11%	169
2024 Q2	$712M	Buy	6,276,504 +1,927,444	+44%	+$244M	0.2%	88
2024 Q1	$603M	Sell	4,349,060 -32,788	-0.7%	-$4.12M	0.21%	84
2023 Q4	$544M	Buy	4,381,848 +290,155	+7%	+$29.6M	0.21%	89
2023 Q3	$382M	Sell	4,091,693 -11,086	-0.3%	-$1.25M	0.17%	118
2023 Q2	$477M	Hold	4,102,779	–	–	0.23%	90
2023 Q1	$477M	Buy	4,102,779 +243,909	+6%	+$27.3M	0.23%	90
2022 Q4	$437M	Sell	3,858,870 -327,741	-8%	-$36M	0.23%	95
2022 Q3	$337M	Buy	4,186,611 +111,825	+3%	+$9.47M	0.19%	109
2022 Q2	$304M	Sell	4,074,786 -45,418	-1%	-$4.15M	0.16%	132
2022 Q1	$527M	Buy	4,120,204 +121,408	+3%	+$13.3M	0.23%	87
2021 Q4	$537M	Sell	3,998,796 -441,944	-10%	-$63.5M	0.21%	107
2021 Q3	$607M	Sell	4,440,740 -160,732	-3%	-$20.3M	0.25%	78
2021 Q2	$491M	Buy	4,601,472 +984,260	+27%	+$94.5M	0.21%	99
2021 Q1	$325M	Buy	3,617,212 +1,934,020	+115%	+$182M	0.14%	144
2020 Q4	$156M	Buy	1,683,192 +474,216	+39%	+$42.3M	0.07%	283
2020 Q3	$125M	Buy	1,208,976 +34,032	+3%	+$3.56M	0.07%	282
2020 Q2	$119M	Sell	1,174,944 -77,980	-6%	-$6.98M	0.07%	266
2020 Q1	$84.3M	Buy	1,252,924 +105,268	+9%	+$6.55M	0.06%	314
2019 Q4	$62.8M	Buy	1,147,656 +63,988	+6%	+$3.04M	0.04%	469
2019 Q3	$40.4M	Buy	1,083,668 +16,952	+2%	+$659K	0.03%	579
2019 Q2	$40M	Sell	1,066,716 -76,068	-7%	-$2.39M	0.03%	594
2019 Q1	$34M	Buy	1,142,784 +157,404	+16%	+$5.53M	0.03%	600
2018 Q4	$29.5M	Buy	985,380 +677,060	+220%	+$21.5M	0.03%	615
2018 Q3	$11M	Buy	308,320 +7,532	+3%	+$234K	0.01%	909
2018 Q2	$7.14M	Sell	300,788 -22,564	-7%	-$478K	0.01%	1032
2018 Q1	$5.99M	Buy	323,352 +33,268	+11%	+$492K	﹤0.01%	1088
2017 Q4	$4.16M	Sell	290,084 -776,904	-73%	-$10.1M	﹤0.01%	1177
2017 Q3	$13.1M	Buy	1,066,988 +15,324	+1%	+$271K	0.01%	836
2017 Q2	$19.2M	Buy	1,051,664 +58,952	+6%	+$1.09M	0.02%	753
2017 Q1	$21M	Buy	992,712 +122,948	+14%	+$2.4M	0.02%	705
2016 Q4	$13M	Sell	869,764 -216,996	-20%	-$3.84M	0.01%	807
2016 Q3	$23.8M	Sell	1,086,760 -187,088	-15%	-$4.16M	0.03%	615
2016 Q2	$25.3M	Buy	1,273,848 +375,516	+42%	+$6.39M	0.03%	579
2016 Q1	$15.3M	Sell	898,332 -55,436	-6%	-$926K	0.02%	746
2015 Q4	$19.5M	Sell	953,768 -18,328	-2%	-$381K	0.02%	676
2015 Q3	$20.9M	Sell	972,096 -10,668	-1%	-$238K	0.02%	663
2015 Q2	$19.6M	Buy	982,764 +35,480	+4%	+$623K	0.02%	723
2015 Q1	$14.8M	Sell	947,284 -3,200	-0.3%	-$48.3K	0.01%	779
2014 Q4	$13.1M	Buy	950,484 +34,400	+4%	+$421K	0.01%	805
2014 Q3	$9.16M	Buy	916,084 +818,092	+835%	+$8.36M	0.01%	864
2014 Q2	$972K	Hold	97,992	–	–	﹤0.01%	1584
2014 Q1	$1.01M	Hold	97,992	–	–	﹤0.01%	1561
2013 Q4	$867K	Sell	97,992 -34,400	-26%	-$272K	﹤0.01%	1569
2013 Q3	$935K	Hold	132,392	–	–	﹤0.01%	1536
2013 Q2	$744K	Buy	+132,392	New	+$634K	﹤0.01%	1553

Other funds holding DXCM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return

UBS AM's DXCM Position: Q1 2026 in Review

UBS AM increased its DexCom (DXCM) stake by 22% in Q1 2026, buying an estimated $122M and bringing the position to 9,746,174 shares worth $612M. The position accounts for 0.13% of the portfolio, ranked #143.

UBS AM first reported a position in DXCM in Q2 2013 and has held it in 52 quarters since. The position peaked at $797M in Q2 2025. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

UBS AM held 9,746,174 shares of DexCom worth $612M as of Q1 2026.
UBS AM bought 1,747,117 DexCom shares in Q1 2026, an estimated $122M.
DexCom made up 0.13% of UBS AM's portfolio in Q1 2026, its #143 holding.
UBS AM first reported a position in DexCom in Q2 2013 and has held it in 52 quarters since.
UBS AM's DexCom position peaked at $797M in Q2 2025.
956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.